Did you complete your Medicaid and CHIP renewal? Renew your benefits on COMPASS.
Brain and Spinal Cord Cancer Clinical Trials
NRG-BN010: A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma.
The purpose of this study is to determine if recurrent glioblastoma can be shrunk or stabilized by adding immune therapy drugs to the usual radiation therapy and if this approach is better or worse than the usual approach for recurrent glioblastoma (The usual approach is treatment with surgery, radiation, or chemotherapy.).
Alliance-A071702: A Phase II Study of Checkpoint Blockade Immunotherapy in Patients with Somatically Hypermutated Recurrent Glioblastoma.
This study is being done to find out if treatment with the combination of immunotherapy drugs nivolumab and ipilimumab is better or worse than the usual approach for recurrent glioblastoma with elevated mutational burden.
NRG-BN011: A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients With Methylated MGMT Promoter Glioblastoma.
The purpose of this study is to compare the usual radiation therapy and usual chemotherapy, temozolomide, to using the usual radiation therapy and usual chemotherapy plus the chemotherapy drug lomustine (Gleostine) to treat MGMT methylated glioblastoma brain tumors.
